Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Research And Development Expense of $1.90 million for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -7.5% in Research And Development Expense from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Research And Development Expense has declined by 61.4%.
- Historical annual values: Fiscal year 2025: $1.90 million | Fiscal year 2024: $2.05 million | Fiscal year 2023: $1.75 million | Fiscal year 2022: $2.39 million | Fiscal year 2021: $2.61 million | Fiscal year 2020: $2.81 million | Fiscal year 2019: $4.00 million | Fiscal year 2018: $4.75 million | Fiscal year 2017: $8.20 million | Fiscal year 2016: $8.21 million | Fiscal year 2015: $11.38 million | Fiscal year 2014: $5.81 million | Fiscal year 2013: $3.60 million | Fiscal year 2012: $5.01 million | Fiscal year 2011: $8.81 million | Fiscal year 2010: $8.42 million | Fiscal year 2009: $4.91 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: